Developer docs
API playgroundTry for free, no card

Search company profiles

HALIX

Full company profile

uuid000mw3e

Namestring
HALIX
Legal namestring
HALIX B.V.
Websiteurl
halix.nl
Company typeenum
Private
Founded yearint
2012
Descriptiontext

HALIX is a Netherlands-based biopharmaceutical contract development and manufacturing organization (CDMO) founded in 2012 as a spin-off of HAL Allergy Group, wholly owned by the German Droege Group AG conglomerate. The company provides end-to-end GMP manufacturing services for biologics across three integrated service lines: viral vector and vaccine manufacturing, recombinant protein and antibody manufacturing, and aseptic fill/finish with lyophilization, serving both small biotech startups and large pharmaceutical companies across preclinical through commercial stages. Its technology platform is built on mammalian expression systems (HEK293, CHO, PER.C6, HeLa, VERO, SF9) with scalable single-use bioreactor capacity up to 1,000 L, supported by 10 EU GMP-grade clean rooms, BSL2 containment with BSL3 upgrade capability, and a 6,700 m² purpose-built facility at Leiden Bio Science Park operational since 2019.

The company's revenue model is project-based contract manufacturing with custom pricing per engagement, driven by direct enterprise sales managed by specialized Business Development directors segmented by therapeutic modality (viral vectors, recombinant proteins, fill/finish). HALIX gained significant commercial credibility through its role in the Oxford/AstraZeneca consortium, manufacturing 80+ million doses of the AZD1222 COVID-19 vaccine following EMA approval in March 2021. In April 2024, HALIX launched the HALiXPEDITE platform to bridge late-stage R&D and GMP manufacturing with an embedded BioHub ecosystem, followed by a December 2024 strategic partnership with Rocketvax for VIRUFLEX pandemic preparedness vaccines. The company employs 70+ staff (per its own description) and reports a 90% customer retention rate across 75+ clients.

Short descriptiontext

HALIX is a Netherlands-based biologics CDMO providing end-to-end GMP manufacturing of viral vectors, vaccines, and recombinant proteins for biotech startups and large pharma from its 6,700 m² Leiden Bio Science Park facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics contract manufacturing, viral vector manufacturing, recombinant protein manufacturing, aseptic fill finish, vaccine CDMO services
Industry5 codes
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

HALIX generates revenue through contract manufacturing agreements for the development and GMP manufacturing of biologics including viral vectors, vaccines, and recombinant proteins. Services span from preclinical to commercial scale, including drug substance and drug product manufacturing, fill-finish, and lyophilization. Revenue is project-based, driven by contracts with pharma and biotech companies for clinical trial material and commercial supply.

halix.nl
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1HALiXPEDITE
Description

A platform bridging late-stage research and GMP manufacturing for biologics therapy development, providing integrated expertise and infrastructure from cell line development to GMP production.

halix.nl
Core offering1 text field

HALIX is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end GMP manufacturing services for viral vectors, vaccines, and recombinant proteins. Services span preclinical to commercial scale, including process development, drug substance and drug product manufacturing, aseptic fill-finish, and lyophilization. The company operates from a 6,700 m² state-of-the-art GMP facility at Leiden Bio Science Park with single-use bioreactor capacity up to 1,000 L and BSL2/BSL3-capable cleanroom infrastructure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 3 billion+ doses of ChAdOx1 COVID-19 vaccine supplied globally through consortium, saving 6 million+ lives
+5 more records
Product overview1 text field

HALIX is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for biologics manufacturing. The core portfolio consists of three integrated service lines: Viral Vector Manufacturing (for oncolytic viruses, gene therapies, and vaccines), Recombinant Protein Manufacturing (for mAbs, bispecific antibodies, and therapeutic proteins), and Aseptic Fill & Finish with Lyophilization. These core products are supported by Development Services for process scale-up, Cell Bank Production, Quality Control/Testing, and Labeling/Packaging. The HALiXPEDITE Platform serves as a unified interface providing integrated expertise from cell line development through GMP manufacturing, complemented by the BioHub ecosystem connecting researchers to IP, AI/ML, and CMC expertise. The company operates mammalian expression systems (CHO, HEK293, PER.C6, HeLa) with capacities up to 1,000 L SUB scale from preclinical through commercial scale.

Product and service5 records
1Viral Vector Manufacturing
CategoryCore CDMO Service
Description

End-to-end GMP manufacturing of viral vectors for oncolytic immunotherapies, cell and gene therapies, and therapeutic/prophylactic vaccines using mammalian expression systems. Supports adenovirus, lentivirus, AAV, and other viral vectors from adherent and suspension cell lines up to 1,000 L SUB scale, intended for pharmaceutical and biotechnology companies from clinical through commercial stage.

2Recombinant Protein Manufacturing
CategoryCore CDMO Service
Description

GMP manufacturing of recombinant proteins and antibodies including monoclonal antibodies, bispecific antibodies, biosimilars, and therapeutic proteins using mammalian expression systems (CHO, HEK293, PER.C6, HeLa cell lines) up to 1,000 L single-use bioreactor scale, serving pharmaceutical and biotechnology companies from clinical through commercial stages.

3Aseptic Fill and Finish with Lyophilization
CategoryCore CDMO Service
Description

GMP-certified aseptic fill and finish services for clinical and commercial scale drug products, including lyophilization cycle development (0.5 m² pilot to 5.0 m² commercial freeze dryer), automated filling line under Grade A in Grade B cleanroom, small and large scale aseptic filling up to 20,000 vials per batch, and BSL2-capable small scale filling for pharmaceutical and biotechnology customers.

4Development Services
CategoryCDMO Development Service
Description

Process development and scale-up services spanning from small scale production to 1,000 L industrial scale, including lyophilization cycle development, analytical development, and QbD/DoE-based process optimization for viral vectors, recombinant proteins, and vaccines, serving pharmaceutical and biotechnology companies from preclinical through clinical stages.

5HALiXPEDITE Platform
CategoryIntegrated CDMO Platform
Description

A platform bridging late-stage research and GMP manufacturing for biologics therapy development, providing integrated expertise and infrastructure from cell line development to GMP production, with access to a BioHub connecting researchers, drug developers, and industry partners to IP, ML/AI, and CMC management through a single point of contact. Targeted at small biotech startups and pharmaceutical companies seeking accelerated biologics development.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-16
Description

HALIX was selected as a strategic CDMO partner for Rocketvax's VIRUFLEX endemic readiness platform and next-generation nasal COVID-19 vaccine. HALIX provides GMP-grade manufacturing, viral vector expertise, and scalable infrastructure. Rocketvax's nasal vaccine uses reverse genetic engineering for live-attenuated SARS-CoV-2, offering nasal immunity, broad protein recognition, transmission prevention, and room-temperature stability.

2U.S. National Institutes of Health (NIH)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-12-16
Description

Rocketvax signed a letter of intent with NIH for clinical development and global access of its nasal COVID-19 vaccine. As HALIX's partner for VIRUFLEX manufacturing, HALIX is indirectly involved in this government collaboration.

halix.nl
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-07-10
Description

HALIX joined the University of Oxford's consortium as an early partner in Q1 2020 to scale up and optimize production of the ChAdOx1 nCoV-19 COVID-19 vaccine. HALIX focused on scaling up and optimizing the production process and producing clinical trial material. The consortium ultimately supplied over 3 billion doses globally. HALIX was named a finalist for the 2024 MacRobert Award alongside Oxford and AstraZeneca.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-22
Description

Strategic partnership for GMP manufacture of clinical trial materials. HALIX produced NVG-111 bispecific antibody from drug substance to drug product in under 7 months. NovalGen's manufacturing process used transient transfection to accelerate timelines and reduce costs.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-12-08
Description

HALIX signed an agreement with AstraZeneca for large-scale commercial drug substance manufacture of AZD1222 COVID-19 vaccine. HALIX expanded with two additional viral vector production lines to meet demand. The facility was EMA-approved in March 2021. HALIX produced commercial batches covering over 80 million vaccine doses.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-04-15
Description

HALIX joined the consortium under University of Oxford's guidance to provide GMP manufacturing services for ChAdOx1 nCoV-19 vaccine. HALIX utilized its new GMP facility with 1,000 L SUB capacity and viral vector expertise to transfer an industrial-scale drug substance process and manufacture clinical trial material.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-15
Description

Part of the University of Oxford ChAdOx1 coronavirus vaccine alliance, alongside the Clinical Biomanufacturing Facility, VMIC, Pall Biotech, and Cobra Biologics. Contributed to viral vector manufacturing and regulatory compliance.

8Cobra Biologics
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-04-15
Description

Part of the University of Oxford ChAdOx1 coronavirus vaccine alliance for viral vector manufacturing and regulatory compliance.

halix.nl
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-12-21
Description

HALIX signed an agreement with Leiden University for a plot of land at the Leiden Bio Science Park. This was the kick-off for the design and construction of HALIX's GMP facility. The Leiden Bio Science Park is the largest science cluster in the Netherlands, bringing together Leiden University, LUMC, and approximately 150 companies.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

World's largest CDMO with extensive biologics, cell & gene therapy, and viral vector capacity across mammalian and microbial platforms. Sets the global benchmark for scale and pricing against which HALIX must position as a more agile European alternative.

TypeBroad incumbent
Description

Global CDMO offering biologics, viral vectors, fill-finish, and cell therapy services at scale; recently acquired by Novo Holdings. Competes for the same pharma and biotech contracts as HALIX across viral vector and fill-finish.

3Cobra Biologics (Charles River)
TypeDirect peer
Description

Viral vector and plasmid DNA CDMO (acquired by Charles River); participated alongside HALIX in the University of Oxford ChAdOx1 manufacturing consortium in 2020. Direct peer in viral vector manufacturing.

TypeDirect peer
Description

Pure-play viral vector CDMO for vaccines, gene therapies, and oncolytic viruses, with BSL2/BSL3 capabilities and AAV/lentiviral expertise. Most direct competitor to HALIX's viral vector manufacturing focus.

TypeBroad incumbent
Description

Diversified CDMO through Patheon providing biologics development, viral vector manufacturing, and fill-finish at global scale. Represents the largest integrated competitor to HALIX across all of HALIX's core services.

TypeDirect peer
Description

Provider of viral vector manufacturing solutions and CDMO services including process development and GMP manufacturing; overlaps with HALIX's transient transfection and viral vector capabilities.

TypeDirect peer
Description

German CDMO for microbial and mammalian biologics including live biotherapeutics and viral vectors. Comparable mid-sized European CDMO focused on GMP contract manufacturing for biologics.

8Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Large biopharmaceutical CDMO offering mammalian- and microbial-based biologics, viral vectors, and aseptic fill-finish services. Strong European competitor that competes with HALIX for both regional biotech and large pharma contracts.

TypeDirect peer
Description

Privately held German CDMO for mammalian cell-culture biologics, recombinant proteins, and viral vectors. Closely comparable mid-sized European CDMO serving both small biotech and large pharma with similar mammalian expression focus.

TypeDirect peer
Description

Global CDMO specializing in mammalian- and microbial-based biologics, viral vectors (AAV, lentiviral), and cell therapy manufacturing. Direct competitor across HALIX's viral vector and recombinant protein service lines, with similar position in clinical and commercial-scale supply.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HALIX

Biopharmaceutical Contract Development and Manufacturing (CDMO)halix.nl

HALIX is a Netherlands-based biologics CDMO providing end-to-end GMP manufacturing of viral vectors, vaccines, and recombinant proteins for biotech startups and large pharma from its 6,700 m² Leiden Bio Science Park facility.

What HALIX does

HALIX is a Netherlands-based biopharmaceutical contract development and manufacturing organization (CDMO) founded in 2012 as a spin-off of HAL Allergy Group, wholly owned by the German Droege Group AG conglomerate. The company provides end-to-end GMP manufacturing services for biologics across three integrated service lines: viral vector and vaccine manufacturing, recombinant protein and antibody manufacturing, and aseptic fill/finish with lyophilization, serving both small biotech startups and large pharmaceutical companies across preclinical through commercial stages. Its technology platform is built on mammalian expression systems (HEK293, CHO, PER.C6, HeLa, VERO, SF9) with scalable single-use bioreactor capacity up to 1,000 L, supported by 10 EU GMP-grade clean rooms, BSL2 containment with BSL3 upgrade capability, and a 6,700 m² purpose-built facility at Leiden Bio Science Park operational since 2019.

The company's revenue model is project-based contract manufacturing with custom pricing per engagement, driven by direct enterprise sales managed by specialized Business Development directors segmented by therapeutic modality (viral vectors, recombinant proteins, fill/finish). HALIX gained significant commercial credibility through its role in the Oxford/AstraZeneca consortium, manufacturing 80+ million doses of the AZD1222 COVID-19 vaccine following EMA approval in March 2021. In April 2024, HALIX launched the HALiXPEDITE platform to bridge late-stage R&D and GMP manufacturing with an embedded BioHub ecosystem, followed by a December 2024 strategic partnership with Rocketvax for VIRUFLEX pandemic preparedness vaccines. The company employs 70+ staff (per its own description) and reports a 90% customer retention rate across 75+ clients.

HALIX firmographics

Firmographics
Name
HALIX
Legal name
HALIX B.V.
Website
https://halix.nl
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
HALIX is a Netherlands-based biologics CDMO providing end-to-end GMP manufacturing of viral vectors, vaccines, and recombinant proteins for biotech startups and large pharma from its 6,700 m² Leiden Bio Science Park facility.
Ownership category
akta.pro rank

HALIX industry classification

Industry
Product category
Biopharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Biologics contract manufacturing
  • Viral vector manufacturing
  • Recombinant protein manufacturing
  • Aseptic fill finish
  • Vaccine CDMO services

Where HALIX is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

HALIX business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: HALIX generates revenue through contract manufacturing agreements for the development and GMP manufacturing of biologics including viral vectors, vaccines, and recombinant proteins. Services span from preclinical to commercial scale, including drug substance and drug product manufacturing, fill-finish, and lyophilization. Revenue is project-based, driven by contracts with pharma and biotech companies for clinical trial material and commercial supply.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

HALIX product offering

Product offering

Core offering

HALIX is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end GMP manufacturing services for viral vectors, vaccines, and recombinant proteins. Services span preclinical to commercial scale, including process development, drug substance and drug product manufacturing, aseptic fill-finish, and lyophilization. The company operates from a 6,700 m² state-of-the-art GMP facility at Leiden Bio Science Park with single-use bioreactor capacity up to 1,000 L and BSL2/BSL3-capable cleanroom infrastructure.

Product overview

HALIX is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for biologics manufacturing. The core portfolio consists of three integrated service lines: Viral Vector Manufacturing (for oncolytic viruses, gene therapies, and vaccines), Recombinant Protein Manufacturing (for mAbs, bispecific antibodies, and therapeutic proteins), and Aseptic Fill & Finish with Lyophilization. These core products are supported by Development Services for process scale-up, Cell Bank Production, Quality Control/Testing, and Labeling/Packaging. The HALiXPEDITE Platform serves as a unified interface providing integrated expertise from cell line development through GMP manufacturing, complemented by the BioHub ecosystem connecting researchers to IP, AI/ML, and CMC expertise. The company operates mammalian expression systems (CHO, HEK293, PER.C6, HeLa) with capacities up to 1,000 L SUB scale from preclinical through commercial scale.

Differentiator

Problem solved

Functional benefit

Brands

  • HALiXPEDITE: A platform bridging late-stage research and GMP manufacturing for biologics therapy development, providing integrated expertise and infrastructure from cell line development to GMP production.

Products and services

  • Viral Vector Manufacturing End-to-end GMP manufacturing of viral vectors for oncolytic immunotherapies, cell and gene therapies, and therapeutic/prophylactic vaccines using mammalian expression systems. Supports adenovirus, lentivirus, AAV, and other viral vectors from adherent and suspension cell lines up to 1,000 L SUB scale, intended for pharmaceutical and biotechnology companies from clinical through commercial stage.
  • Recombinant Protein Manufacturing GMP manufacturing of recombinant proteins and antibodies including monoclonal antibodies, bispecific antibodies, biosimilars, and therapeutic proteins using mammalian expression systems (CHO, HEK293, PER.C6, HeLa cell lines) up to 1,000 L single-use bioreactor scale, serving pharmaceutical and biotechnology companies from clinical through commercial stages.
  • Aseptic Fill and Finish with Lyophilization GMP-certified aseptic fill and finish services for clinical and commercial scale drug products, including lyophilization cycle development (0.5 m² pilot to 5.0 m² commercial freeze dryer), automated filling line under Grade A in Grade B cleanroom, small and large scale aseptic filling up to 20,000 vials per batch, and BSL2-capable small scale filling for pharmaceutical and biotechnology customers.
  • Development Services Process development and scale-up services spanning from small scale production to 1,000 L industrial scale, including lyophilization cycle development, analytical development, and QbD/DoE-based process optimization for viral vectors, recombinant proteins, and vaccines, serving pharmaceutical and biotechnology companies from preclinical through clinical stages.
  • HALiXPEDITE Platform A platform bridging late-stage research and GMP manufacturing for biologics therapy development, providing integrated expertise and infrastructure from cell line development to GMP production, with access to a BioHub connecting researchers, drug developers, and industry partners to IP, ML/AI, and CMC management through a single point of contact. Targeted at small biotech startups and pharmaceutical companies seeking accelerated biologics development.

Quantifiable outcome

  • 3 billion+ doses of ChAdOx1 COVID-19 vaccine supplied globally through consortium, saving 6 million+ lives
  • +5 more outcomes

Companies that use HALIX

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

HALIX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

HALIX partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

  • Rocketvax AGcoreStrategic or Co-development Partner · 16 December 2024HALIX was selected as a strategic CDMO partner for Rocketvax's VIRUFLEX endemic readiness platform and next-generation nasal COVID-19 vaccine. HALIX provides GMP-grade manufacturing, viral vector expertise, and scalable infrastructure. Rocketvax's nasal vaccine uses reverse genetic engineering for live-attenuated SARS-CoV-2, offering nasal immunity, broad protein recognition, transmission prevention, and room-temperature stability.
  • U.S. National Institutes of Health (NIH)flagshipStrategic or Co-development Partner · 16 December 2024Rocketvax signed a letter of intent with NIH for clinical development and global access of its nasal COVID-19 vaccine. As HALIX's partner for VIRUFLEX manufacturing, HALIX is indirectly involved in this government collaboration.
  • University of OxfordflagshipStrategic or Co-development Partner · 10 July 2024HALIX joined the University of Oxford's consortium as an early partner in Q1 2020 to scale up and optimize production of the ChAdOx1 nCoV-19 COVID-19 vaccine. HALIX focused on scaling up and optimizing the production process and producing clinical trial material. The consortium ultimately supplied over 3 billion doses globally. HALIX was named a finalist for the 2024 MacRobert Award alongside Oxford and AstraZeneca.
  • NovalGencoreStrategic or Co-development Partner · 22 February 2021Strategic partnership for GMP manufacture of clinical trial materials. HALIX produced NVG-111 bispecific antibody from drug substance to drug product in under 7 months. NovalGen's manufacturing process used transient transfection to accelerate timelines and reduce costs.
  • AstraZenecaflagshipStrategic or Co-development Partner · 8 December 2020HALIX signed an agreement with AstraZeneca for large-scale commercial drug substance manufacture of AZD1222 COVID-19 vaccine. HALIX expanded with two additional viral vector production lines to meet demand. The facility was EMA-approved in March 2021. HALIX produced commercial batches covering over 80 million vaccine doses.
  • University of Oxford Jenner InstituteflagshipStrategic or Co-development Partner · 15 April 2020HALIX joined the consortium under University of Oxford's guidance to provide GMP manufacturing services for ChAdOx1 nCoV-19 vaccine. HALIX utilized its new GMP facility with 1,000 L SUB capacity and viral vector expertise to transfer an industrial-scale drug substance process and manufacture clinical trial material.
  • Vaccine Manufacturing and Innovation Centre (VMIC)minorStrategic or Co-development Partner · 15 April 2020Part of the University of Oxford ChAdOx1 coronavirus vaccine alliance, alongside the Clinical Biomanufacturing Facility, VMIC, Pall Biotech, and Cobra Biologics. Contributed to viral vector manufacturing and regulatory compliance.
  • Cobra BiologicsminorStrategic or Co-development Partner · 15 April 2020Part of the University of Oxford ChAdOx1 coronavirus vaccine alliance for viral vector manufacturing and regulatory compliance.
  • Leiden UniversitycoreStrategic or Co-development Partner · 21 December 2017HALIX signed an agreement with Leiden University for a plot of land at the Leiden Bio Science Park. This was the kick-off for the design and construction of HALIX's GMP facility. The Leiden Bio Science Park is the largest science cluster in the Netherlands, bringing together Leiden University, LUMC, and approximately 150 companies.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

HALIX competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: World's largest CDMO with extensive biologics, cell & gene therapy, and viral vector capacity across mammalian and microbial platforms. Sets the global benchmark for scale and pricing against which HALIX must position as a more agile European alternative.
  • Catalent (Novo Holdings): Global CDMO offering biologics, viral vectors, fill-finish, and cell therapy services at scale; recently acquired by Novo Holdings. Competes for the same pharma and biotech contracts as HALIX across viral vector and fill-finish.
  • Thermo Fisher Scientific (Patheon CDMO): Diversified CDMO through Patheon providing biologics development, viral vector manufacturing, and fill-finish at global scale. Represents the largest integrated competitor to HALIX across all of HALIX's core services.
  • Boehringer Ingelheim BioXcellence: Large biopharmaceutical CDMO offering mammalian- and microbial-based biologics, viral vectors, and aseptic fill-finish services. Strong European competitor that competes with HALIX for both regional biotech and large pharma contracts.

Direct peers

  • Cobra Biologics (Charles River): Viral vector and plasmid DNA CDMO (acquired by Charles River); participated alongside HALIX in the University of Oxford ChAdOx1 manufacturing consortium in 2020. Direct peer in viral vector manufacturing.
  • Vibalogics: Pure-play viral vector CDMO for vaccines, gene therapies, and oncolytic viruses, with BSL2/BSL3 capabilities and AAV/lentiviral expertise. Most direct competitor to HALIX's viral vector manufacturing focus.
  • Polyplus ( transfection / process solutions): Provider of viral vector manufacturing solutions and CDMO services including process development and GMP manufacturing; overlaps with HALIX's transient transfection and viral vector capabilities.
  • Wacker Biotech: German CDMO for microbial and mammalian biologics including live biotherapeutics and viral vectors. Comparable mid-sized European CDMO focused on GMP contract manufacturing for biologics.
  • Rentschler Biologics: Privately held German CDMO for mammalian cell-culture biologics, recombinant proteins, and viral vectors. Closely comparable mid-sized European CDMO serving both small biotech and large pharma with similar mammalian expression focus.
  • AGC Biologics: Global CDMO specializing in mammalian- and microbial-based biologics, viral vectors (AAV, lentiviral), and cell therapy manufacturing. Direct competitor across HALIX's viral vector and recombinant protein service lines, with similar position in clinical and commercial-scale supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

HALIX social profiles

Digital presence

HALIX compliance and trust

Trust signal

Compliance5 records

HALIX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HALIX leadership team

Management profile

Number of profiles

Profiles8 records

HALIX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HALIX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HALIX

What does HALIX do?

HALIX is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end GMP manufacturing services for viral vectors, vaccines, and recombinant proteins. Services span preclinical to commercial scale, including process development, drug substance and drug product manufacturing, aseptic fill-finish, and lyophilization. The company operates from a 6,700 m² state-of-the-art GMP facility at Leiden Bio Science Park with single-use bioreactor capacity up to 1,000 L and BSL2/BSL3-capable cleanroom infrastructure.

Is HALIX a public or private company?

HALIX is a private company. It is classified as corporate owned and is currently operating.

When was HALIX founded?

HALIX was founded in 2012. It employs 11 to 50 people.

Where is HALIX based?

HALIX is headquartered in Leiden, Netherlands, in the Europe region.

How does HALIX make money?

One revenue line is on record: contract Development and Manufacturing (CDMO) Services.

Who are HALIX's main competitors?

Broad incumbents on record are Lonza Group, Catalent (Novo Holdings), Thermo Fisher Scientific (Patheon CDMO) and Boehringer Ingelheim BioXcellence. Direct peers are Cobra Biologics (Charles River), Vibalogics, Polyplus ( transfection / process solutions), Wacker Biotech, Rentschler Biologics and AGC Biologics.

Does HALIX have an API?

No public API is recorded for HALIX.

What industry is HALIX in?

HALIX's product category is Biopharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales